Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Psychiatric, Neurological, and Somatic Comorbidities in Intermittent Explosive Disorder.
JAMA Psychiatry
January 2025
Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, New York.
Importance: Intermittent explosive disorder (IED) is an understudied psychiatric condition marked by impulsive aggression and poorly regulated emotional control, often resulting in interpersonal and societal consequences. Better understanding of comorbidities can improve screening, diagnosis, and treatment.
Objective: To investigate the prevalence of IED and its associations with psychiatric, neurological, and somatic disorders.
Does Alexithymia Predict the Psychiatric Comorbidity Among Healthy Carriers of Hepatitis B?
Alpha Psychiatry
November 2024
Department of Psychiatry, Freelance Physician, İstanbul, Türkiye.
Objective: The psychiatric disorders among healthy carriers of hepatitis B (HBsAg), who have no severe physical disability or any medical treatment, have clinical importance. We aimed to research the comorbid psychiatric disorders and alexithymia and to identify whether alexithymia and accompanying somatic symptoms predict the presence of psychiatric diagnoses or not among HBsAg carriers.
Methods Eighty-nine: healthy carriers of Hepatitis B patients and nınety-three healthy individuals were included to study.
Predicting work ability impairment in post COVID-19 patients: a machine learning model based on clinical parameters.
Infection
January 2025
Department of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
The Post COVID-19 condition (PCC) is a complex disease affecting health and everyday functioning. This is well reflected by a patient's inability to work (ITW). In this study, we aimed to investigate factors associated with ITW (1) and to design a machine learning-based model for predicting ITW (2) twelve months after baseline.
View Article and Find Full Text PDFDemographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review.
Psychiatry Res
January 2025
Department of Psychiatry, University Medical Center Groningen, Groningen, the Netherlands.
Accumulating evidence supports the efficacy of (es)ketamine in the treatment of major depressive disorder (MDD), particularly treatment-resistant depression (TRD). Yet around 50% of the individuals with TRD do not respond to (es)ketamine. Elucidating predictors of response and remission could improve treatment outcomes at the individual level by defining subpopulations that are most likely to benefit from (es)ketamine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!